Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Braun DL, Hampel B, Kouyos R, Nguyen H, Shah C, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Böni J, Fehr JS; Swiss HIV Cohort Study. Braun DL, et al. Among authors: boni j. Clin Infect Dis. 2019 Feb 1;68(4):569-576. doi: 10.1093/cid/ciy547. Clin Infect Dis. 2019. PMID: 30107485 Free article.
HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy.
Schüpbach J, Böni J, Bisset LR, Tomasik Z, Fischer M, Günthard HF, Ledergerber B, Opravil M; Swiss HIV Cohort Study. Schüpbach J, et al. Among authors: boni j. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):292-9. doi: 10.1097/00126334-200307010-00002. J Acquir Immune Defic Syndr. 2003. PMID: 12843739 Clinical Trial.
HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load.
Oxenius A, Price DA, Hersberger M, Schlaepfer E, Weber R, Weber M, Kundig TM, Böni J, Joller H, Phillips RE, Flepp M, Opravil M, Speck RF; Swiss HIV Cohort Study. Oxenius A, et al. Among authors: boni j. J Infect Dis. 2004 Apr 1;189(7):1199-208. doi: 10.1086/382028. Epub 2004 Mar 17. J Infect Dis. 2004. PMID: 15031788 Free article.
Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.
Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study. Joos B, et al. Among authors: boni j. J Virol. 2005 Jul;79(14):9026-37. doi: 10.1128/JVI.79.14.9026-9037.2005. J Virol. 2005. PMID: 15994796 Free PMC article.
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
Schüpbach J, Günthard H, Joos B, Fischer M, Böni J, Tomasik Z, Yerly S, Perrin L, Battegay M, Furrer H, Vernazza P, Bernasconi E, Hirschel B; Swiss HIV Cohort Study. Schüpbach J, et al. Among authors: boni j. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):250-6. doi: 10.1097/01.qai.0000181281.75670.56. J Acquir Immune Defic Syndr. 2005. PMID: 16249697 Clinical Trial.
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. von Wyl V, et al. Among authors: boni j. Arch Intern Med. 2007 Sep 10;167(16):1782-90. doi: 10.1001/archinte.167.16.1782. Arch Intern Med. 2007. PMID: 17846398
494 results